HGP-1805
- Generic Name
- HGP-1805
Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease
Phase 3
Completed
- Conditions
- Non-erosive Gastroesphageal Reflux Disease
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Hanmi Pharmaceutical Company Limited
- Target Recruit Count
- 208
- Registration Number
- NCT04325620
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath